ArticleBMC surgery2026
Papillary thyroid carcinoma in graves' disease: prevalence, clinicopathological features, and preoperative predictors.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coexistence of Graves' disease (GD) and papillary thyroid carcinoma (PTC) remains a subject of clinical debate. While PTC is frequently detected incidentally after thyroidectomy for GD, its prevalence, clinicopathological behavior, and preoperative predictors remain insufficiently defined.
methodsThis single-center retrospective cohort study included 602 patients who underwent thyroidectomy between 2020 and 2025. Patients were categorized as: GD + PTC (n = 51); GD-only (n = 109); and PTC-only (n = 442). Demographic, biochemical, radiological, surgical, and pathological data were analyzed. Univariate and multivariate logistic regression models were used to identify factors associated with PTC development in GD.
resultsThe prevalence of PTC among GD patients was 31.9%. Compared with sporadic PTC, GD-associated tumors were smaller (median 5 mm vs. 12 mm, p < 0.001) and demonstrated fewer aggressive features including lymphatic invasion, capsular invasion, multifocality, bilaterality, and nodal metastasis (all p < 0.01). GD + PTC patients were younger and showed a lower female predominance than those with sporadic PTC. When compared with GD-only patients, the GD + PTC group had significantly lower thyroid-stimulating Immunoglobulin (TSI) titers (median 3.8 vs. 7.65 IU/L, p = 0.007) and a higher prevalence of ultrasound-detected thyroid nodules (64.7% vs. 27.5%, p < 0.001). In multivariate analysis, only US-detected nodules (OR 3.56, p = 0.003) and lower TSI levels (OR 0.95, p = 0.03) independently predicted PTC in GD.
conclusionPTC is relatively common among surgically treated GD patients, yet presents predominantly as microcarcinoma with less aggressive histopathological features. The presence of ultrasound-detected thyroid nodules was the strongest preoperative predictor of malignancy. These findings support careful and systematic ultrasonographic assessment in patients with GD, with FNAB guided by established ultrasound risk patterns, nodule size thresholds, and high-risk clinical features, rather than indiscriminate lowering of biopsy thresholds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.